TY - JOUR
T1 - Type 2 (subretinal) neovascularization in agerelated macular degeneration associated with pure reticular pseudodrusen phenotype
AU - Naysan, Jonathan
AU - Jung, Jesse J
AU - Dansingani, Kunal K
AU - Balaratnasingam, Chandrakumar
AU - Freund, K Bailey
PY - 2016/3
Y1 - 2016/3
N2 - PURPOSE: To report the association of pure type 2 neovascularization (NV) in age-related macular degeneration occurring almost exclusively in patients with reticular pseudodrusen.METHODS: An observational retrospective cohort study of all eyes receiving antivascular endothelial growth factor therapy for newly diagnosed neovascular age-related macular degeneration by a single practitioner over a 6-year period. Only patients with treatment-naive, pure type 2 NV who also had either pre-neovascular imaging of the study eye or imaging of a nonneovascular fellow eye available to determine baseline characteristics including drusen type and choroidal thickness were incuded.RESULTS: Of 694 patients treated for neovascular age-related macular degeneration, only 8 met the inclusion criteria with pure type 2 NV. Of these, 7 (88%) had exclusively reticular pseudodrusen (5 in the nonneovascular fellow eye, 2 in the study eye before developing NV). Six (75%) patients in the affected neovascular eye and 6 (75%) in the fellow nonneovascular eye had choroidal thickness <120 μm. Mean follow-up was 46 months (range, 3.0-63.3). Best-corrected vision improved from 20/89 (range, 20/30-20/796) at baseline to 20/60 (range, 20/20-20/399) at last follow-up.CONCLUSION: Pure type 2 NV is rare in age-related macular degeneration, occurring almost exclusively in patients with reticular pseudodrusen and thin choroids.
AB - PURPOSE: To report the association of pure type 2 neovascularization (NV) in age-related macular degeneration occurring almost exclusively in patients with reticular pseudodrusen.METHODS: An observational retrospective cohort study of all eyes receiving antivascular endothelial growth factor therapy for newly diagnosed neovascular age-related macular degeneration by a single practitioner over a 6-year period. Only patients with treatment-naive, pure type 2 NV who also had either pre-neovascular imaging of the study eye or imaging of a nonneovascular fellow eye available to determine baseline characteristics including drusen type and choroidal thickness were incuded.RESULTS: Of 694 patients treated for neovascular age-related macular degeneration, only 8 met the inclusion criteria with pure type 2 NV. Of these, 7 (88%) had exclusively reticular pseudodrusen (5 in the nonneovascular fellow eye, 2 in the study eye before developing NV). Six (75%) patients in the affected neovascular eye and 6 (75%) in the fellow nonneovascular eye had choroidal thickness <120 μm. Mean follow-up was 46 months (range, 3.0-63.3). Best-corrected vision improved from 20/89 (range, 20/30-20/796) at baseline to 20/60 (range, 20/20-20/399) at last follow-up.CONCLUSION: Pure type 2 NV is rare in age-related macular degeneration, occurring almost exclusively in patients with reticular pseudodrusen and thin choroids.
KW - Aged
KW - Aged, 80 and over
KW - Angiogenesis Inhibitors/therapeutic use
KW - Bevacizumab/therapeutic use
KW - Cohort Studies
KW - Extracellular Space
KW - Female
KW - Humans
KW - Intravitreal Injections
KW - Macular Degeneration/complications
KW - Male
KW - Optical Imaging
KW - Phenotype
KW - Ranibizumab/therapeutic use
KW - Receptors, Vascular Endothelial Growth Factor/therapeutic use
KW - Recombinant Fusion Proteins/therapeutic use
KW - Retinal Drusen/complications
KW - Retinal Neovascularization/diagnosis
KW - Retrospective Studies
KW - Tomography, Optical Coherence
KW - Vascular Endothelial Growth Factor A/antagonists & inhibitors
KW - Visual Acuity/physiology
U2 - 10.1097/IAE.0000000000000758
DO - 10.1097/IAE.0000000000000758
M3 - Article
C2 - 26383711
SN - 0275-004X
VL - 36
SP - 449
EP - 457
JO - Retina (Philadelphia, Pa.)
JF - Retina (Philadelphia, Pa.)
IS - 3
ER -